Pursuits
Gilead’s Hepatitis C Drug Patent Challenged by Medical Charity
This article is for subscribers only.
Gilead Sciences Inc.’s patent for the blockbuster hepatitis C drug Sovaldi is being challenged by a medical-aid charity, which claims the intellectual-property protection allows the company to charge “unsustainable” prices.
The legal action was filed with the European Patent Office in Munich, Germany, Doctors of the World said in a statement. The medical group says overturning the patent would open up access to cheaper versions of the medicine.